Medicine and Dentistry
Ethinylestradiol
100%
Medroxyprogesterone Acetate
52%
Patient
35%
Low Drug Dose
23%
Endometrial Hyperplasia
23%
Incidence
17%
Hyperplasia
11%
Postmenopause
11%
Woman
11%
Estrogen
5%
Osteoporosis
5%
Placebo-Controlled Study
5%
Endometrial Biopsy
5%
Hormone Substitution
5%
Gestagen
5%
Age
5%
Therapeutic Procedure
5%
Amaurosis
5%
Women's Health
5%
Uterus
5%
Nursing and Health Professions
Premarin
100%
Medroxyprogesterone Acetate
52%
Low Drug Dose
23%
Pathologist
23%
Incidence
17%
Dose
11%
Hyperplasia
11%
Clinician
5%
Osteoporosis
5%
Placebo-Controlled Study
5%
Hormone Substitution
5%
Placebo
5%
Protection
5%
Blindness
5%
Estrogen
5%
Gestagen
5%
Endometrium Biopsy
5%
Pharmacology, Toxicology and Pharmaceutical Science
Conjugated Estrogen
100%
Medroxyprogesterone Acetate
52%
Endometrium Hyperplasia
23%
Incidence
17%
Hyperplasia
11%
Placebo-Controlled Study
5%
Estrogen
5%
Osteoporosis
5%
Progestin
5%
Blindness
5%
Biochemistry, Genetics and Molecular Biology
Equus
100%
Medroxyprogesterone Acetate
52%
Low Drug Dose
23%
Incidence
17%
Postmenopause
11%
Dose
11%
Women's Health
5%
Age
5%
Immunology and Microbiology
Equus
100%
Low Drug Dose
23%
Incidence
17%
Postmenopause
11%
Dose
11%
Uterus
5%
Women's Health
5%
Age
5%